0001209191-23-002775.txt : 20230110
0001209191-23-002775.hdr.sgml : 20230110
20230110161416
ACCESSION NUMBER: 0001209191-23-002775
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20230101
FILED AS OF DATE: 20230110
DATE AS OF CHANGE: 20230110
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Shook David
CENTRAL INDEX KEY: 0001959742
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39370
FILM NUMBER: 23521293
MAIL ADDRESS:
STREET 1: 6000 SHORELINE COURT, SUITE 102
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nkarta, Inc.
CENTRAL INDEX KEY: 0001787400
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 474515206
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6000 SHORELINE COURT
STREET 2: SUITE 102
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 415-582-4923
MAIL ADDRESS:
STREET 1: 6000 SHORELINE COURT
STREET 2: SUITE 102
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2023-01-01
0
0001787400
Nkarta, Inc.
NKTX
0001959742
Shook David
C/O NKARTA, INC.
6000 SHORELINE COURT, SUITE 102
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Chief Medical Officer
Common Stock
22977
D
Stock Option (right to buy)
18.00
2030-07-08
Common Stock
13300
D
Stock Option (right to buy)
18.00
2030-07-08
Common Stock
4300
D
Stock Option (right to buy)
18.00
2030-07-08
Common Stock
4800
D
Stock Option (right to buy)
54.89
2031-01-07
Common Stock
4680
D
Stock Option (right to buy)
31.85
2031-04-29
Common Stock
150
D
Stock Option (right to buy)
12.14
2032-01-13
Common Stock
3310
D
Stock Option (right to buy)
18.44
2032-04-28
Common Stock
5000
D
Stock Option (right to buy)
13.86
2032-05-15
Common Stock
7000
D
Stock Option (right to buy)
12.25
2032-06-16
Common Stock
35000
D
Stock Option (right to buy)
16.46
2032-08-19
Common Stock
30000
D
Includes 1,660 Restricted Stock Units ("RSUs") which vest in four equal annual installments beginning on January 14, 2023, 5,000 RSUs which vest in four equal annual installments beginning on June 17, 2023, and 15,000 RSUs which vest in four equal annual installments beginning on August 20, 2023. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.
The option is vested and exercisable as to 8,589 shares, and the remaining shares will vest and become exercisable ratably in monthly installments until fully vested on June 1, 2024.
The option is vested and exercisable as to 2,687 shares, and the remaining shares will vest and become exercisable ratably in monthly installments until fully vested on July 1, 2024.
The option is vested and exercisable as to 3,000 shares, and the remaining shares will vest and become exercisable ratably in monthly installments until fully vested on July 9, 2024.
The option is vested and exercisable as to 2,340 shares, and the remaining shares will vest and become exercisable ratably in monthly installments until fully vested on January 8, 2025.
The option is vested and exercisable as to 62 shares, and the remaining shares will vest and become exercisable ratably in monthly installments until fully vested on April 30, 2025.
The option is vested and exercisable as to 759 shares, and the remaining shares will vest and become exercisable ratably in monthly installments until fully vested on January 14, 2026.
The option is vested and exercisable as to 833 shares, and the remaining shares will vest and become exercisable ratably in monthly installments until fully vested on April 29, 2026.
The option is vested and exercisable as to 1,021 shares, and the remaining shares will vest and become exercisable ratably in monthly installments until fully vested on May 16, 2026.
The option is vested and exercisable as to 4,375 shares, and the remaining shares will vest and become exercisable ratably in monthly installments until fully vested on June 17, 2026.
The option is vested and exercisable as to 2,500 shares, and the remaining shares will vest and become exercisable ratably in monthly installments until fully vested on August 20, 2026.
/s/ Alicia Hager, as Attorney-in-Fact
2023-01-10
EX-24
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
FOR SEC FILINGS ON FORMS ID, 3, 4, 5 AND 144
The undersigned hereby constitutes and appoints each of Paul Hastings, Chief
Executive Officer, and Alicia Hager, JD, PhD, Chief Legal Officer, of Nkarta,
Inc., a Delaware corporation (the "Company"), so long as each is employed at the
Company, and C. Brophy Christensen and Regina Braman, each of O'Melveny & Myers
LLP ("OMM"), outside counsel to the Company, so long as each is employed at OMM,
as his true and lawful attorney-in-fact and agent (each, an "Attorney-In-Fact"),
with full power of substitution and resubstitution for him and in his name and
stead in any and all capacities, to sign and file for and on his behalf, in
respect of any acquisition, disposition or other change in ownership of any of
the securities of the undersigned, the following:
(i) any Form ID to be filed with the Securities and Exchange Commission (the
"SEC");
(ii) any Update Passphrase Request to be filed with the SEC;
(iii) any Initial Statement of Beneficial Ownership of Securities on Form 3 to
be filed with the SEC;
(iv) any Statement of Changes of Beneficial Ownership of Securities on Form 4 to
be filed with the SEC;
(v) any Annual Statement of Beneficial Ownership of Securities on Form 5 to be
filed with the SEC;
(vi) any Notice of Proposed Sale of Securities on Form 144 to be filed with the
SEC; and
(vii) any and all agreements, certificates, receipts, or other documents in
connection therewith.
The undersigned hereby gives full power and authority to each Attorney-In-Fact
to seek and obtain as his representative and on his behalf, information on
transactions in the securities of the undersigned from any third party,
including brokers, employee benefit plan administrators and trustees, and the
undersigned hereby authorizes any such third party to release such information
to each Attorney-In-Fact and approves and ratifies any such release of
information.
The undersigned hereby grants unto each Attorney-In-Fact full power and
authority to do and perform each and every act and thing requisite and necessary
in connection with such matters and hereby ratifies and confirms all that any
such Attorney-In-Fact or substitute may do or cause to be done by virtue hereof.
The undersigned acknowledges that:
(i) neither the Company nor any Attorney-In-Fact assumes (i) any liability for
the undersigned's responsibility to comply with the requirement of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"), (ii) any
liability of the undersigned for any failure to comply with such requirements or
(iii) any obligation or liability of the undersigned for profit disgorgement
under Section 16(b) of the Exchange Act; and
(ii) this Power of Attorney does not relieve the undersigned from responsibility
for compliance with the undersigned's obligations under the Exchange Act,
including without limitation the reporting requirements under Section 16 of the
Exchange Act.
This Power of Attorney shall remain in full force and effect with respect to the
undersigned until revoked by the undersigned in a signed writing delivered to
each Attorney-In-Fact.
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK.]
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 21st day of December, 2022.
/s/ DAVID SHOOK
____________________
DAVID SHOOK